Insider · CIK 0001387660

Carter Eric G

Reports to the SEC for 4 companies · IRVINE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001387660

Forms 4 and 5

Insider transactions

45 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-17	AEONAEON Biopharma, Inc.A Award	Director	AAward	+223K sh	—	—	258,705
2025-05-21	AEONAEON Biopharma, Inc. · Restricted Stock UnitsA Award	Director	AAward	+309K sh	—	—	308,641
2024-08-31	AEONAEON Biopharma, Inc.A Award	Director	AAward	+36K sh	—	—	36,021
2024-08-31	AEONAEON Biopharma, Inc. · Stock OptionA Award	Director	AAward	+96.2K sh	—	—	96,210
2024-03-19	AEONAEON Biopharma, Inc. · Stock OptionA Award	Director	AAward	+16.3K sh	—	—	16,260
2024-03-19	AEONAEON Biopharma, Inc. · Stock OptionA Award	Director	AAward	+8,130 sh	—	—	8,130
2023-08-14	AEONAEON Biopharma, Inc. · Stock OptionA Award	Director	AAward	+58.9K sh	—	—	58,851
2023-07-21	AEONAEON Biopharma, Inc. · Stock OptionA Award	Director	AAward	+9,007 sh	—	—	9,007
2023-07-21	AEONAEON Biopharma, Inc. · Stock OptionA Award	Director	AAward	+11.8K sh	—	—	11,802
2020-06-23	Adverum Biotechnologies, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2019-07-31	Adverum Biotechnologies, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+45K sh	—	—	45,000
2018-05-31	Adverum Biotechnologies, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+35K sh	—	—	35,000
2018-04-23	ALDER BIOPHARMACEUTICALS INCStock Option (Right to Buy)A Award	Interim Chief Medical Officer	AAward	+75K sh	—	—	75,000
2017-09-07	Adverum Biotechnologies, Inc.A Award	Director	AAward	+48K sh	—	—	48,000
2017-09-07	Adverum Biotechnologies, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+69K sh	—	—	69,000
2011-01-31	KING PHARMACEUTICALS INCStock Option (Right to Buy)J Other	Chief Science Officer	JOther	−34.2K sh	—	—	0
2011-01-31	KING PHARMACEUTICALS INCStock Option (Right to Buy)J Other	Chief Science Officer	JOther	−42.2K sh	—	—	0
2011-01-31	KING PHARMACEUTICALS INCStock Option (Right to Buy)J Other	Chief Science Officer	JOther	−50.3K sh	—	—	0
2011-01-31	KING PHARMACEUTICALS INCU Disposition from Tender	Chief Science Officer	UDisposition from Tender	−135K sh	—	—	38,740
2011-01-31	KING PHARMACEUTICALS INCD Disposition to Issuer	Chief Science Officer	DDisposition to Issuer	−38.7K sh	—	—	0
2011-01-31	KING PHARMACEUTICALS INCPerformance Share UnitsD Disposition to Issuer	Chief Science Officer	DDisposition to Issuer	−55.7K sh	—	—	0
2011-01-31	KING PHARMACEUTICALS INCPerformance Share UnitsD Disposition to Issuer	Chief Science Officer	DDisposition to Issuer	−17.9K sh	—	—	0
2011-01-18	KING PHARMACEUTICALS INCLong-Term Performance UnitA Award	Chief Science Officer	AAward	+17.9K sh	—	—	17,860
2011-01-07	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+16.3K sh	—	—	136,227
2011-01-07	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+16.3K sh	—	—	174,167
2010-12-31	KING PHARMACEUTICALS INCM Exercise/Conversion	Chief Science Officer	MExercise/Conversion	+37.9K sh	—	—	174,167
2010-12-31	KING PHARMACEUTICALS INCLong-Term Performance UnitM Exercise/Conversion	Chief Science Officer	MExercise/Conversion	−37.9K sh	—	—	0
2010-11-29	KING PHARMACEUTICALS INCF Tax Payment	Chief Science Officer	FTax Payment	−40.4K sh	$14.15	−$572K	119,967
2010-03-22	KING PHARMACEUTICALS INCF Tax Payment	Chief Science Officer	FTax Payment	−1,772 sh	$12.25	−$21.7K	164,514
2010-03-17	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+12K sh	—	—	166,286
2010-03-17	KING PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Chief Science Officer	AAward	+42.2K sh	—	—	42,240
2010-03-10	KING PHARMACEUTICALS INCF Tax Payment	Chief Science Officer	FTax Payment	−4,121 sh	$12.22	−$50.4K	160,393
2010-02-25	KING PHARMACEUTICALS INCLong-Term Performance UnitA Award	Chief Science Officer	AAward	+55.7K sh	—	—	55,740
2010-01-25	KING PHARMACEUTICALS INCF Tax Payment	Chief Science Officer	FTax Payment	−4,523 sh	$12.35	−$55.9K	154,316
2009-12-31	KING PHARMACEUTICALS INCLong-Term Performance UnitM Exercise/Conversion	Chief Science Officer	MExercise/Conversion	−12.7K sh	—	—	0
2009-12-31	KING PHARMACEUTICALS INCM Exercise/Conversion	Chief Science Officer	MExercise/Conversion	+12.7K sh	—	—	158,839
2009-03-23	KING PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Chief Science Officer	AAward	+50.3K sh	—	—	50,290
2009-03-23	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+15.9K sh	—	—	146,141
2009-03-10	KING PHARMACEUTICALS INCF Tax Payment	Chief Science Officer	FTax Payment	−534 sh	$6.31	−$3,369.54	130,211
2009-02-17	KING PHARMACEUTICALS INCLong-Term Performance UnitA Award	Chief Science Officer	AAward	+37.9K sh	—	—	37,940
2009-01-16	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+1,645 sh	—	—	130,745
2009-01-16	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+1,645 sh	—	—	130,745
2007-11-29	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+100K sh	—	—	118,260
2007-03-21	KING PHARMACEUTICALS INCStock Option (Right to Buy)A Award	Chief Science Officer	AAward	+10.8K sh	—	—	10,750
2007-03-21	KING PHARMACEUTICALS INCA Award	Chief Science Officer	AAward	+5,460 sh	—	—	18,260

Recent filings

Accepted (ET)
Jun 224
Carter Eric G0001104659-26-076509
SEC(opens sec.gov)
May 234
Carter Eric G0001610717-25-000131
SEC(opens sec.gov)
Sep 44
Carter Eric G0001104659-24-097061
SEC(opens sec.gov)
Mar 214
Carter Eric G0001104659-24-037434
SEC(opens sec.gov)
Aug 164
Carter Eric G0001104659-23-092542
SEC(opens sec.gov)
Jul 244
Carter Eric G0001104659-23-083568
SEC(opens sec.gov)
Jun 254
Carter Eric G0001209191-20-038958
SEC(opens sec.gov)
Aug 24
Carter Eric G0001209191-19-044256
SEC(opens sec.gov)
Jun 154
Carter Eric G0001209191-18-038058
SEC(opens sec.gov)
Apr 254
Carter Eric G0001209191-18-026121
SEC(opens sec.gov)
Sep 84
Carter Eric G0001209191-17-052148
SEC(opens sec.gov)
Feb 24
Carter Eric G0001209191-11-006508
SEC(opens sec.gov)

Companies

Address

C/O AEON BIOPHARMA, INC. 5 PARK PLAZA, SUITE 1750

IRVINE, CA, 92614